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Vaccines have significantly reduced the detrimental effects of numerous human infectious 
diseases worldwide, helped to reduce drastically child mortality rates and even achieved 
eradication of major pathogens, such as smallpox. These achievements have been 
possible due to a dedicated effort for vaccine research and development, as well as an 
effective transfer of these vaccines to public health care systems globally. Either public or 
private institutions have committed to developing and manufacturing vaccines for local 
or international population supply. However, current vaccine manufacturers worldwide 
might not be able to guarantee sufficient vaccine supplies for all nations when epidem-
ics or pandemics events could take place. Currently, different countries produce their 
own vaccine supplies under Good Manufacturing Practices, which include the USA, 
Canada, China, India, some nations in Europe and South America, such as Germany, 
the Netherlands, Italy, France, Argentina, and Brazil, respectively. Here, we discuss some 
of the vaccine programs and manufacturing capacities, comparing the current models 
of vaccine management between industrialized and developing countries. Because 
local vaccine production undoubtedly provides significant benefits for the respective 
population, the manufacture capacity of these prophylactic products should be included 
in every country as a matter of national safety.
Keywords: vaccine manufacturing, immunization programs, vaccine distribution, vaccine shortages, good 
manufacturing practices
iNTRODUCTiON
The incidence of numerous infectious diseases that are life threatening to humans has drastically 
declined since the development of safe and effective vaccines and the implementation of global 
vaccination programs worldwide. In fact, the variola virus, which caused smallpox disease that 
killed millions of individuals throughout history, was successfully eradicated from Earth during the 
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1980s (1), due to a worldwide immunization campaign against 
this major pathogen. Moreover, poliovirus, which severely affects 
the health of children with lifelong disabling consequences, has 
almost been eradicated from the world. Since 1999 very few 
cases of polio disease have been reported, probably due to two of 
the three poliovirus types. Indeed, the goal of the World Health 
Organization (WHO) is to achieve the eradication of polio dur-
ing 2018. Therefore, millions of human lives have been saved by 
means of the implementation of national immunization programs 
in all countries, and the demand for new prophylactics to protect 
against infectious diseases is constantly growing. Although vac-
cine manufacturing is usually associated with biopharmaceutical 
companies, some public and academic institutions also produce 
these prophylactic formulations (2). Despite the existence of those 
manufacturers aiming at increasing vaccine availability, shortage 
of these products has taken place several times causing that not 
enough doses were available in some countries.
In this article, we attempt to comprehensively discuss the 
WHO current recommendations for routine immunization and 
some of the national immunization programs. Further, we associ-
ate such vaccination programs to the global vaccine manufacture 
and distribution capabilities, focusing in some industrialized and 
developing countries. The comparison between these two types 
of nations was done to point out key management differences 
among them, when aiming at guaranteeing prophylaxis against 
serious infectious diseases in their populations. In addition, we 
also examined the dependency on foreign vaccine supply of some 
countries, classifying them according to their capacity to supply 
the local demand with domestic facilities or via importation from 
other states.
vACCiNeS CURReNTLY ReCOMMeNDeD 
BY THe wHO
According to the WHO, children should be immunized with 
bacille Calmette–Guerin (BCG), diphtheria-tetanus-acellular 
pertussis (DTaP), MMR (combines Mumps, Measles, and Rubella), 
and vaccines to prevent Hepatitis B, poliovirus, Haemophilus 
influenzae type B (Hib), several serotypes of Streptococcus pneu-
moniae, rotavirus, and papillomavirus (3). In addition to these 
vaccines for children, the influenza vaccine is also recommended 
to be administered in certain susceptible groups, such as pregnant 
women, healthcare workers, children aged 6–59 months and the 
elderly (>65 years old) (3). Furthermore, the coverage of routine 
Expanded Program on Immunization (EPI), which includes vac-
cines against tuberculosis (TB), diphtheria, tetanus, and pertus-
sis, polio and measles, varies from country to country (Figure 1).
vaccination for Poliomyelitis: An example 
of a Nearly eradicated Disease
Although poliomyelitis cases decreased greatly in 1988, 
74 cases of this disease were reported in 2015. The majority 
of them occurred in Pakistan and in Afghanistan. Therefore, 
the goal proposed by the WHO is to eradicate poliomyelitis 
by 2018. Poliomyelitis is an infection caused by poliovirus that 
affects the human nervous system (4). The trivalent attenuated 
oral polio vaccine (tOPV), which includes the types 1, 2, and 3, 
has been used since the beginning of the 1960s. However, due 
to the polio type 2 vaccine components were pointed out as the 
infectious source leading to a large number of cases of vaccine-
derived polioviruses, global initiatives have suggested to switch 
from the trivalent to a bivalent polio vaccine. Such vaccine only 
includes type 1 and 3 viruses (5). Interestingly, the wild type 
poliovirus type 2 has not been reported since 1999 and was 
declared eradicated in September 2015. Besides, the poliovirus 
type 3 has not been detected since 2012 and the poliovirus type 
1 is likely the only strain remaining in circulation.
As an additional effort to keep population protected against 
all types of poliovirus during the eradication program, the WHO 
instructed to include at least one dose of the inactivated polio 
vaccine (IPV) in the sequential shift from the tOPV toward the 
dOPV (6). The IPV is composed by the three types of poliovirus, 
which is intramuscularly administered. Clinical trials in children 
have shown that this vaccine is an excellent booster and capable 
of enhancing the mucosal immune response in primed subjects 
(4, 7).The future goal is to shift from dOPV to IPV at the time 
when type 1 and 3 polioviruses were eradicated.
vaccination for Respiratory Diseases:  
TB, Pneumonia, and influenza
A different vaccine type, the BCG vaccine, has been used in over 
a billion people since 1921 to prevent TB (8). Although not able 
to induce a strong protective immunity in adults, the BCG vac-
cine has been shown to protect against meningitis TB disease in 
children (9). However, the BCG vaccine currently is not utilized 
in children from countries with low rates of TB incidence, such 
as the USA, Spain, Australia, Norway, Canada, and England (10). 
In those countries, the BCG vaccine is only recommended for 
those children showing a negative tuberculin skin test and that 
are continually exposed to adults with untreated or ineffectively 
treated for TB disease. Further, BCG vaccination is also recom-
mended for health care workers in settings of frequent exposure 
to TB patients (11). Furthermore, because the BCG vaccine 
derives from attenuated bacteria passaged in the 1960s, the large 
number of passages affecting the banks available today has led to 
multiple genetic changes in the bacilli. Several studies supported 
the notion that this genetic divergence could be responsible for 
the variant protective capacity against TB shown by the various 
BCG vaccine strains (8, 12). Thus, an efficient BCG vaccine that 
provides full protection is still required. The major BCG manu-
facturers prequalified by the WHO are the Staten Serum Institute 
(Denmark), Serum Institute of India Ltd., Japan BCG Laboratory, 
and Intervax Ltd. (Canada). In addition, some Asian and Eastern-
European countries possess their own locally-produced BCG 
vaccine, such as China (China National Biotec Group), Serbia 
(Torlak Institute), and Vietnam (IVAC) (8).
Bacteria-caused pneumonia, due to infection with vari-
ous serotypes of S. pneumoniae (Pneumococcal disease) and 
Hib display a high rate of morbidity and mortality worldwide, 
although nowadays, the majority of the deaths take place in 
sub-Saharan Africa and Asia (13). Both pneumococcal and Hib 
vaccines are recommended by the WHO (3). However, not all 
FigURe 1 | Immunization programs around the world. Vaccines funded by national governments and included in national immunization programs by continent and 
regional examples. BCG, bacille Calmette–Guerin; HepB, hepatitis B virus; DTaP combines protection against diphtheria, tetanus, and pertussis; MMR, combines 
mumps, measles and rubella; Hib, Haemophilus influenzae type B; HPV, human papillomavirus; JE, Japanese encephalitis live vaccine. Exemptions: BCG is given in 
some countries of Europe. HPV is given in some countries of Africa.
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countries include these vaccines in their national immuniza-
tion programs and, for instance, the public health systems of 
some South Asian countries do not use them at all (Figure 1). 
Thus, whereas these vaccines were introduced in the 1990s in 
most industrialized countries, still these prophylactics are not 
funded by public health systems in some developing countries, 
such as South Asian nations. Consequently, still 18/100,000 and 
26/10,000 cases of Hib were reported in children younger than 
5 years old in Vietnam and in China, respectively. To handle these 
high incidence rates, organizations including the Global Alliance 
for Vaccine and Immunization (GAVI) and the United Nations 
International Children’s Emergency Fund have financed pneu-
mococcal and Hib vaccines to provide coverage for developing 
countries (14). Several studies conclusively have supported the 
notion that public health systems should add these vaccines to 
their national immunization programs with their own funding, 
in every developing country. Thus, adopting these measures, the 
incidence of these major infectious diseases could be reduced 
(15, 16). Further, some GAVI-supported countries experienced 
a transition from GAVI-derived support to a fully self-financed 
Hib vaccination program. Thereby, strategic immunization plans 
are required to provide vaccines to their population (17).
Viral respiratory diseases generated by the influenza virus 
causes low rates of mortality but high rates of morbidity world-
wide every year (18–20). This seasonal disease is mainly caused 
by two types of influenza viruses: A and B (21). The influenza A 
virus displays a high rate of variation causing frequent antigenic 
changes, in a process known as antigen drift. For this reason, 
the influenza vaccine confers only limited-time protection (up 
to 2  years) and it is necessary to reformulate and manufacture 
new influenza vaccines every year. Influenza vaccination is 
recommended by the WHO for high-risk individuals, including 
children, pregnant women, healthcare workers, the elderly and 
individuals suffering from chronic conditions, such as asthma, 
diabetes and heart disease (3). Further, organizations such as 
the American Academy of Pediatrics recommend the seasonal 
influenza vaccination for children of 6  months and older (22). 
However, the coverage of this vaccine still remains low despite the 
influenza vaccination strategies, including government involve-
ment and national programs (23). Importantly, pandemic influenza 
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H1N1 emerged in 2009, affecting mainly children and the elderly. 
The global number of deaths during the first 12 months of virus 
circulation was reported from 151,700 to 575,400 people (24). 
Moreover, the older age groups presented higher severity in post-
pandemic influenza outbreaks (25).
vaccination to Prevent Diphtheria, 
Tetanus, and whopping Cough
Another vaccine of global relevance is the DTaP (14). This 
vaccine protects against three severe infectious diseases: 
diphtheria, tetanus, and pertussis. First, diphtheria is caused by 
Corynebacterium diphtheria, which produces pharyngeal infec-
tion, myocarditis, polyneuropathy, and systemic toxicity (26). 
Second, tetanus is caused by Clostridium tetani and the typical 
symptoms include muscle spam and contraction (26). Finally, 
pertussis, also known as whopping cough, is caused by Bortedella 
pertussis, which can produce loss of weight, subconjunctival 
hemorrhages, and syncope (26). Currently these three diseases 
circulate in the population worldwide and the highest rates 
are observed in children from countries with low vaccination 
coverage, especially in developing countries (27–29). However, 
and despite high vaccination coverage, several outbreaks have 
recently been reported in industrialized countries (30). For 
instance, an outbreak in the USA was reported in 2012, resulting 
in 48,277 cases of pertussis (31). According to the United States 
Center for Disease Control and Prevention (CDC), DTaP pro-
tects from whopping cough in 7 out of 10 vaccinated subjects, 
while it efficiently protects against the severe illness. In fact, the 
introduction of DTaP vaccine in the USA reduced from 100,000 
to 32,000 cases of pertussis per year. Despite these good results, 
DTaP could fail to provide long-lasting protection in humans 
(31). It is important to indicate that the WHO estimates that 
there still are about 16 million cases of pertussis and 30,000 of 
diphtheria per year worldwide, being the highest rates in India 
(32). Therefore, these infections are still an important public 
health burden that requires close monitoring.
vaccination to Prevent Cervical Cancer
The nine-valent human papillomavirus vaccine (HPV) is recom-
mended for routine vaccination of girls at age of 9 or 10 years 
old to confer protection against cervical cancer caused by the 
HPV (33). This new vaccine is significantly more expensive as 
compared to the other vaccines. Thereby, although it is highly 
recommended vaccine, not all children are being immunized 
to prevent this cancer (33). Despite the fact that the first HPV 
vaccine was available in 2006, today only two biopharmaceutical 
companies manufacture this vaccine (33). A study performed 
in France showed 95.93% effectiveness for the HPV vaccine in 
sexually active young women (34). Despite such effectiveness, a 
strong parent refusal remains in several countries to vaccinate 
children against HPV due to safety and effectiveness concerns, as 
reported in a survey in the USA (35).
vaccination to Prevent Diarrheal Diseases
Another recent vaccine included in the immunization programs 
of several industrialized and developing countries is the one 
to prevent rotavirus-infections (3). This virus is one the most 
common causes of severe gastroenteritis with diarrhea-related 
hospitalizations in children worldwide, which shows in particu-
lar high mortality rates in developing countries (36). The WHO 
has recommended that this vaccine should be included in all 
national immunization programs, being strongly recommended 
for countries showing a high mortality rate in children under 
5 years old due to severe dehydrating diarrhea (37). Nowadays, 
an increasing number of countries, such as the USA and Germany 
have incorporated the rotavirus vaccine in their national immu-
nization programs. A meta-analysis conducted on individuals 
of Europe, North America and Latin America showed that this 
vaccine has an efficacy of 53% against rotavirus infections, 73% 
against rotavirus-related hospitalizations, and 74% against severe 
diarrhea episodes (38).
vaccination to Prevent Typhoid Fever
Typhoid fever is a life-threatening systemic disease caused by 
human adapted Salmonella enterica serovars, such as Typhi, 
Paratyphi A, Paratyphi B, and Paratyphi C (39, 40). These 
are Gram negative enterobacteria that infect humans by con-
tamination of food and water supplies, causing disseminated 
infections that compromise internal organs, such as spleen, 
liver, bone marrow, and blood (39, 41). The incidence of these 
diseases is low in industrialized countries (less than 10 cases 
per 100,000) and high in developing countries, specifically 
in Asia and in Africa (more than 100 per 100,000) (42–44). 
Importantly, a significant increase in S. paratyphi A has been 
reported in the last years in Asian countries, reporting up 
to 44-fold increase in the period 2007–2013 in Cambodia 
(45). Currently, there are three licensed vaccines to prevent 
typhoid fever: The Vivotif®, Typbar®, and the Typhim V® 
vaccines. The Vivotif® is a live attenuated vaccine approved 
by the FDA for use in humans, based on the Ty21a strain, 
which was generated in the 1970 by chemical mutagenesis 
(46). This vaccine was previously produced and distributed by 
Crucell Switzerland It Ltd., but recently the American com-
pany PaxVax has acquired the license for this product. This 
vaccine is provided as a lyophilized formulation (in capsules) 
and used orally to promote mucosal immunity against these 
bacteria. A large clinical study performed in Chile showed 
that the rate of protection after three immunizations was 69% 
(47). In contrast, the Typhim Vi® and Typbar® are inactivated 
vaccines consisting of the Vi capsular polysaccharide, which 
are produced by Sanofi Pasteur and Bharat Biotech, respec-
tively (48). The Typhim Vi® vaccine is administered intra-
muscularly and confers an antibody-based protection (49). 
The rate of protection for this vaccine is close to 75% (50). 
Further, those vaccines do not confer cross-immune protection 
against S. Paratyphy A, for which does not exist a licensed vac-
cine available to prevent disease caused by this bacterium (51). 
Because of the immune memory conferred by both vaccines 
are very limited, their inclusion in immunization programs 
has not been recommended. However, the use of this vaccine 
has been encouraged by the WHO, especially when sanitation 
measures are threatened, for instance during natural disasters 
that impair the accessibility to clean water. Nevertheless, due 
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to the growing emergence of antibiotic-resistant strains of S. 
Typhi in developing countries like India, the permanent use 
of these vaccines, as well as the generation of improved ones, 
would be highly appropriate to apply in their populations (52).
vaccination to Prevent Meningitis
Meningitis is an inflammation of the membranes covering the 
brain and spinal cord known as meninges, which can be caused 
by viral, bacterial or fungal infection, but also by due to non-
infectious causes, as it has been reported (53). The main bacterial 
agents responsible for this disease are S. pneumoniae, Hib, and N. 
meningitidis, which could be prevented by available vaccines (54). 
Meningococcal disease has been reported worldwide, but largest 
epidemics have affected mainly sub-Saharan African countries, 
known as the “meningitis belt” having 430 million of high-risk 
population (53, 55).
According to the recent report in May 2017 by the CDC 
(56), there are two types of meningococcal vaccines available 
in the USA. The first vaccine is based on bacterial conjugates: 
Menactra® and Menveo®, both conferring protection against 
A, C, W, and Y meningococcal serogroups. The second is a 
serogroup B recombinant meningococcal vaccine: Bexsero® 
and Trumenba®. An additional vaccine, named MenAfriVac® 
(produced by the Serum Institute of India Private Ltda.), confers 
protection against N. meningitidis serogroup A (Nm A), which 
is the most prevalent in the African “meningitis belt” (55). The 
MenAfriVac® vaccine was a result of collaborative efforts between 
the WHO and the PATH in the Meningitis Vaccine Project, with 
the purpose of developing a vaccine against the specific agent 
affecting importantly the health of the African population, 
presenting a low-cost manufacturing and being independent of 
the cold chain distribution (57, 58). Since the national routine 
immunization strategic plan started in 2010, the incidence of 
Nm A meningitis fell from 0.27 per 100,000 in 2004–2010 to 0.02 
per 100,000 in 2011–2013 (59). According to the recent WHO 
weekly record, 19 of the 26 countries belonged to the African 
“meningitis belt” have shown a sustained decreased incidence 
for Nm A cases, which means a reduction by at least 57% of the 
meningitis burden in that area (55). Also, clinical trials demon-
strated that MenAfriVac® decreases carriage rates in immunized 
populations and provides herd immunity probably because 
of the high antibody titers observed during the development 
and safety testing of the vaccine (60, 61). Due to the national 
immunization program for this vaccine was a success, Ghana 
and Sudan currently include the MenAfriVac® in their routine 
immunization schedule (55). Despite the significant decrease 
in the prevalence on Nm A, it is important to highlight the 
necessity to continue with immunization programs to guarantee 
protection against different serogroups (62). Further, experts 
alert of the possible serogroup replacement, following applica-
tion of massive immunization programs (63). In fact, in 2015 
an epidemic with a novel strain of N. meningitidis serogroup 
C was reported in Niger and Nigeria. In addition, in 2016 the 
principal N. meningitidis serogroup W was found in Ghana and 
Togo, although with a low number of cases (55). For that reason, 
the continuous research in this area is a central challenge toward 
elimination of meningococcal meningitis epidemics in Africa.
vACCiNe TYPeS, MANUFACTURiNg 
PROCeDUReS, AND CURReNT 
ReSeARCH ON MANUFACTURiNg 
STATUS
Types of vaccines and Manufacturing 
Procedures
Vaccines can be classified as live-attenuated, inactivated, sub 
units, recombinant, conjugated, toxoids, or DNA, according to 
the final preparation of the microorganism or antigen (64). Live-
attenuated and inactivated microorganisms cover the major frac-
tion of licensed vaccines for use in humans. Smallpox, BCG, yellow 
fever, polio, chickenpox, rotavirus, typhoid fever (Ty21a vaccine), 
and influenza are examples of licensed vaccines produced with 
live attenuated microorganisms (8, 65–67). On the other hand, 
examples of inactivated vaccines include those preventing plague, 
whooping cough, influenza, polio, typhoid fever (Vi capsular 
polysaccharide vaccine), and hepatitis A diseases (5, 49, 68–72). 
Only few vaccines are produced using recombinant technologies 
(hepatitis B virus, influenza, HPV) or via purification of partial 
components of a microorganism [S. Typhi Vi capsular polysaccha-
ride, diphtheria, tetanus, pneumococcus, meningococcus, Hib, 
pertussis toxoid, and anthrax protective antigen (PA)] (73, 74). 
However, there has been an increased interest in the usage of 
these technologies in the past years (75).
There are different methods of vaccines production, which 
include isolation of microorganisms from either infected tissues 
(e.g., smallpox), bacteria growth in fermenters (e.g., vaccines for 
TB, typhoid fever, plague, whooping cough, diphtheria, tetanus, 
pneumococcus, meningococcus, pertussis, anthrax), isola-
tion from virus grown in cell cultures (e.g., polio, chickenpox, 
rotavirus, hepatitis A virus (HAV), influenza) or isolation from 
virus grown in eggs (e.g., influenza, yellow fever). For the case 
of bacteria grown in fermenters, is not the microorganism itself 
that is used for the vaccine elaboration, rather some of its compo-
nents from cell-free filtrates (e.g., vaccines for tetanus, pertussis, 
anthrax). For example, the anthrax vaccine adsorbed consists in 
the PA purified from filtrates by precipitation with alum, which 
also serves as an adjuvant (76).
An interesting change in the way of manufacturing has been 
recently carried out for influenza vaccines, which has been 
produced for more than 50 years in embryonated chicken eggs 
(77). However, GlaxoSmithKline (GSK) and Seqirus are cur-
rently producing influenza virus using cell culture technology 
in bioreactors (approved by the FDA in 2012) to generate new 
licensed influenza vaccines (78). Likewise, the Kaketsuken vac-
cine company is working on the development of a cell culture-
based process, using the EB66 cell line, to elaborate a vaccine 
for pandemic flu, which is currently under clinical studies (79, 
80). More recently, the Protein Sciences Corporation received 
approval for commercialization of a licensed novel influenza 
vaccine consisting of purified recombinant hemagglutinin 
antigens expressed in insect cell cultures (81). Similar efforts are 
in progress toward the development of cell culture-based yellow 
fever vaccines using Vero cell cultures in microcarriers (82). For 
anthrax, a plant-derived recombinant protective antigen has been 
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developed as a vaccine, which is currently under evaluation in 
clinical trials (76, 83).
Thus, cell culture technologies, together with the enhance-
ment of upstream and downstream processes, will bring 
production efficiencies to a next level as compared to the egg-
based technology, and will increase manufacturing speed and 
capacities, thereby avoiding the shortage of these vaccines in the 
future (84, 85).
vaccine Research in the industry versus 
the Academia
Vaccine portfolios in many pharmaceutical companies have 
decreased in the last decades due to the cost and time involved for 
vaccine development, which are much more costly and time con-
suming to develop than other drugs (86). However, pharmaceuti-
cal companies as well as academic institutions are continuously 
investing in vaccine research. For example, the number of vaccines 
in development has increased about twofold, according to a study 
comprising the 1995–2008 period in the USA (87). This fact can 
be explained, in part, by the advancement of alternative technolo-
gies, such as baculovirus-based recombinant vaccines, virus-like 
particles, viral vectors and RNA or DNA vaccines (74, 88–93). 
Moreover, with a world population projected to be of 10 billion 
by 2050, a 90% of it is estimated to live in developing countries 
(United Nations projection) (94). Thus, the subsequent increase 
in the vaccine market from USD 25 billion by today to USD 100 
billion by 2025, will continue to encourage vaccine research and 
development (95).
Many research groups in academic institutions have made 
considerable efforts on vaccine discovery and research, but only 
few of them have been able to move forward into the development 
vaccine process. A reduced technology transfer efficiency may be 
due to difficulties on establishing private-academy license agree-
ments (LA) (96). Indeed, Public-Private-Partnerships (PPP) has 
shown to be relevant for some vaccine developments, such as for 
the prototype of HIV vaccine (97). Thus, these LA and PPP enable 
the implementation of new and improved vaccines in high-tech 
centers before a product is transferred into the market. Another 
factor is the requirement of facilities with Good Manufacturing 
Practicing (GMP) certification and high-quality personnel to 
develop vaccine production processes. The staff capacities and 
facilities to investigate, develop and manufacture vaccines are key 
to respond rapidly to the global emergencies, such as the recent 
Ebola outbreak (98).
The increase of vaccine manufacturers has impacted on the 
global market, allowing to lower the prices of vaccines and to 
improve the global demand. Further, partnerships, such as GAVI 
Alliance, UNICEF, and the WHO have also been key for enhanc-
ing that kind of vaccine production in developing countries 
(99). As example, the new vaccine manufacturing countries 
such Brazil, the Russian Federation, India, China, and South 
Africa (known as BRICS) play a substantial and increasing 
role in the global vaccine market. These countries not only 
produce traditional vaccines at competitive low costs and 
under the WHO-prequalified standards, but they also gener-
ate innovative products due to current strategic alliances with 
multinational corporations (99, 100). The most successful 
case of this strategic alliance, is the Bio-Manguinho plant 
in Brazil, that will be producing an affordable measles and 
rubella vaccine with the support of the Bill & Melinda Gates 
Foundation together with the Brazilian Ministry of Health (100). 
An arising number of pharmaceuticals along with the NIH are 
interested in enlarging the number of vaccines manufactured in 
those institutes, which in turn involved discussion of the agree-
ment of the Trade Related Aspects of Intellectual Property Rights.
DiveRSiTY OF iMMUNiZATiON 
PROgRAMS wORLDwiDe: RegiONAL 
eXAMPLeS AND THe gAP BeTweeN 
iNDUSTRiALiZeD AND DeveLOPiNg 
COUNTRieS
Worldwide, the diversity in national immunization programs 
is extensive, therefore the list of vaccines included and distrib-
uted in each country shows significant differences (Figure  1). 
Furthermore, the vaccination plan for the USA might even be dif-
ferent depending on the state, while in Europe the immunization 
plans have significant differences among the countries belonging 
to the European Union (Figure 1). On the other hand, there are 
variations in the financing mechanisms for vaccine production 
within Europe. For instance, the National Health System funds 
the rotavirus vaccine in Germany, but not in Spain. Other vac-
cines, such as the live attenuated Japanese encephalitis, cholera, 
and yellow fever vaccines are recommended only in some Asian 
countries, such as in India and in Thailand. Furthermore, 
meningococcal C conjugate vaccines are included in the National 
Health System of Australia, Chile, and Spain, but not in those 
of Asian countries like in India. Another example of diversity 
on immunization schedule is the BCG vaccine against TB. This 
vaccine is being administered only in some countries in Europe, 
Asia, Africa, and South America, but it is not administered in 
industrialized countries such as in the USA (14). Table 1 sum-
marizes the differences of the immunization programs between 
seven countries, including industrialized and developing coun-
tries (101, 102).
Germany is an example where vaccination is mostly volun-
tary with a reduced role of the state in the implementation of 
vaccination programs. Around 90% of the vaccines are given by 
private physicians and only the remaining small fraction of the 
vaccines is given by public institutions, schools or daycare centers 
(103). Massive school immunization programs are not manda-
tory, but the immunization status is checked at schools. This 
information is collected and documented by the Robert Koch 
Institute. The Berlin measles outbreak of 2015 and the death of 
a non-vaccinated infant raised the discussion as to whether vac-
cination in Germany must be mandatory (104). This discussion 
has been intensified considering that the Europe is confronting 
the largest immigration since the World War II. The collapse of 
national immunization programs in the countries undergoing 
political turmoil has led to children-disease outbreaks, which 
could have been prevented by vaccination. Moreover, refugees 
are susceptible to diseases due to overcrowding, physical and 
TABLe 1 | National immunization programs of seven countries.
BCg HepB Polio DTaP MMR HPv Hib Pneumococcal Rotavirus Je
USA 2, 4, and  
6 months old
2, 4, 6 months and  
11 years old
2, 4, and 6 months old 12 months old >11 years old 2, 4, and 6 and 
>12 months old
2, 4, and 6 and 
>12 months old
2, 4, and 
6 months old
Chilea Newborn 2, 4, and  
6 months old
2, 4, 6 months and  
12–13 years old
2, 4, and 6 months old 12 months old 10 years old 2, 4, and  
6 months old
12 months old
Germany  2, 3, 4,  
11–14 months old
2, 3, 4, 11–14 months  
and 5–6 and  
9–11 years old





9–14 years old 2, 4, 4, and 
12–14 months old
2, 4, and 
11–14 months old
6 weeks, 2 and 
4 months old
Spain 2, 4, 6 months old 2, 4, 6, and  
18 months old
2, 4, 6, and 18 months  
old, and 6 years old
12 months and 
3–4 years old
12–14 years old 2, 4, 6, and 
18 months old
2, 4, and 
11 months oldb
Chinaa Newborn Newborn, 1 and 
6 months old
2, 3, 4 months, and  
4 years old
3, 4, 5, and from 18 to  
24 months years old
18–24 months old 8 months and 
6 years old
Indiaa Newborn Newborn 6, 10, 14 weeks, and 
16–24 months old
6, 10, 14 weeks, and 
16–24 months old
9, 16–24 monthsc 9, 16–24 months 
old
South Africaa Newborn 6, 10, 14 weeks  
and, 18 months old
Newborn, 6 weeks 6, 10, 14 weeks, and  
18 months old
9 and 18 monthsc 6, 10, 14 weeks, 
and 18 months old
6, 14 weeks, and 
9 months old
6 and 14 weeks 
old
Developed and developing countries were selected according to their geographical area and income. Orange: not funded by the public health system. Blue: funded by the public health system.
aDeveloping countries.
bDepends on the region, this vaccine is included in the public health system.
cOnly vaccine against measles.
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psychological stress, malnutrition and low availability of sanitary 
systems. These health aspects and conditions constitute a serious 
threat to immigrants, as well as to international programs aimed 
at eradicating vaccine-preventable diseases. Recent studies of 
measles, mumps, rubella, and varicella seroprevalence in refugees 
in Germany have shown satisfactory immunity in adults but low 
seroprevalence in children, suggesting thorough and prompt vac-
cination of children entering Europe (105). The opposite has been 
found for hepatitis A immunity in refugees in Germany, where 
the high rate of HAV protection supports the thesis that the prob-
ability of large HAV outbreaks in current German refugee centers 
is low (71). Nevertheless, vaccination of refugees against HAV is 
highly recommended.
The immunization programs in the USA follow the CDC guide-
lines (106). In this country, as mentioned earlier, vaccine coverage 
differs widely among states, varying for instance with ≥2 doses 
of HAV from 41.2% in Mississippi to 72.8% in Nebraska (107). 
Recent nonmedical exemptions in immunization laws have 
prompted serious concerns about potential vaccine coverage 
weakening. However, after the recent outbreaks of vaccine-
preventable diseases mandatory immunizations at entry-schools 
and primary care facilities have emerged. Indeed, those states 
that allow exemptions, including religious and philosophical 
reasons, have shown a significantly higher incidence of vaccine-
preventable diseases, as compared to those states allowing less 
exceptions for vaccination (108). Interestingly, the coverage of 
vaccines in the USA will depend on the insurance plan of each 
individual. Accordingly to the CDC, the coverage of children aged 
19–35 months was lower in those children uninsured or covered 
by public insurance programs, such as Medicaid, as compared 
to private insurance-covered kids (107). However, some the 
USA vaccine manufacturers and the National Vaccine Programs 
offer help to those people who cannot afford some vaccines, 
such as the one for HPV. Importantly, up to 32.9% of children of 
19–35 months of age in the USA live below poverty level and can 
fail to receive all the required vaccines (107). To overcome this 
problem, the Vaccines for Children Program in the US offers free 
vaccines to children living in poverty (107).
In South America, the Pan-American Health Organization 
(OPS) provides a caring cooperation system, named the “Fondo 
Rotatorio,” designed to obtain the vaccines recommended by the 
WHO at low prices (109). As for the case of Chile, the Public 
Health Institute and the Ministry of Health direct the Chilean 
National Immunization Program (CNIP) following international 
recommendations. Vaccines included in the CNIP are funded 
by the government and given to hospitals, family health centers 
and some schools in Chile. The introduction of the latest vaccines 
in the CNIP has significantly reduced the incidence of certain 
diseases, such as bacteria-caused pneumonia and cervical cancer. 
One example is the 10-valent pneumococcal vaccine, which was 
introduced in January 2011 and thereafter, the number of hospitali-
zations due to pneumonia were successfully reduced (110). Such 
effectiveness of the 10-valent pneumococcal vaccine has also been 
demonstrated in other South-American countries (111). In 2015, 
the Chilean government supported the introduction of the HPV 
vaccine in the CNIP and thereby, most of 9–10 years old girls have 
been vaccinated since then as a program to prevent cervical cancer.
Thus, each country has its own national immunization 
program (112), which in most cases includes vaccines that are 
sponsored by their public health systems reaching different levels 
of coverage (Figure 2). Nevertheless, many developing countries 
have difficulties to finance all the vaccines recommended by the 
WHO. As a result, different organizations have arisen to provide 
economical support to the developing countries requiring vac-
cines. For instance, the Global Vaccine Activation Plan (GVAP) 
has established itself the goal of reducing some vaccine-prevent-
able diseases by 2020 (113). Moreover, most traditional vaccines 
are sold at lower prices to organizations, such as UNICEF and 
the Pan-American Health Organization to reach developing 
countries (14). Although global coverage has improved, in 
countries such as India, Nigeria, Pakistan and Indonesia, a low 
immunization coverage still exist (113). It is noteworthy that 35 of 
the 45 classified as lower-middle income countries by the World 
Bank Classification are not being supported by GVAP Alliance, 
thereby these countries are struggling to reach underused and 
new vaccines to immunize their children (14). Also, one of the 
GVAP goals was to eliminate the maternal and neonatal tetanus, 
measles, and rubella in 2014, but unfortunately this goal was not 
achieved (113). One of the main reasons for this failure has been 
the unstable political situation in some countries and the inef-
ficient introduction of these vaccines in national immunization 
programs (113). Therefore, economical gaps still remain between 
industrialized and developing countries to accomplish efficient 
immunization programs for their children. With globalization, 
leading to increased and fast movements of goods and people 
traveling to all remote areas in the world, these differences in 
health protection can be a risk for outbreaks, epidemics or even 
worse, pandemics. Importantly, several organizations includ-
ing the GAVI Alliance, UNICEF, the Bill & Melinda Gates 
Foundation, the United States National Institute of Allergies and 
Infectious Diseases, the WHO, together with governments and 
other institutions support the goals of the GVAP to reduce some 
vaccine-preventable diseases by 2020 (113).
vACCiNe MANUFACTURe AND 
DiSTRiBUTiON: STATUS OF ACADeMiC, 
PUBLiC, AND PRivATe MANUFACTURiNg 
COMPANieS
vaccine Production and Distribution
Although mainly private pharmaceutical companies have 
engaged in vaccine manufacturing and distribution, there are 
also successful efforts made by academic or public institutions 
to achieve this goal (Table  2). Vaccine manufacturing requires 
specific and expensive facilities with high scale production, and 
quality standards to ensure consistency and controlled elabora-
tion of these products. This is typically achieved following the 
guidelines of the current (c) GMP in compliance with the local 
regulatory authorities. Therefore, most of the countries have 
contract agreements with specific cGMP-certified manufactur-
ers to purchase the vaccines required for their populations. For 
example, the private sector is in charge of the 5–10% of the vac-
cines market in Asia (114).
FigURe 2 | Coverage for Extended Program of Immunization (EPI). *EPIs include those against tuberculosis, diphtheria, tetanus, and pertussis (DTP), polio, and 
measles, as well as those protecting newborn children and their mothers against tetanus by vaccination of pregnant women. Data obtained from WHO/UNICEF 
reports 2007 and 2014 reports.
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The USA is one example of a country, in which both private 
and public sectors provide vaccines for their population (115). 
This is an advantage, because the public health system can choose 
from different sources and prices. The main pharmaceutical 
companies that produce and distribute vaccines around the 
world include GSK, the United Kingdom; Pfizer, the USA; Sanofi 
Pasteur, France; Merck & Co., the USA; Roche, France; Seqirus, 
Australia; Valneva SE, France (Table  2). In addition, emerging 
pharmaceutical companies, such as Astellas Pharma, Japan; 
Takeda, Japan, and AstraZeneca, United Kingdom currently 
invest in vaccine R&D. Other international companies, including 
the Serum Institute of India and the Bharat Biotech International 
supply vaccines to countries without local vaccine manufacture 
facility, such as Chile. Particularly, the Serum Institute of India is 
a state-owned vaccine manufacturing center that produces most 
of the vaccines recommended by the WHO including BCG, polio, 
Hib, DTaP, and MMR. Similarly, national public enterprises, 
including the Immunobiological Technology Guinhos (Bio-
Manguinhos/Fiocruz) and the Butantan Institute supply most of 
the vaccines in Brazil (Table 2). Importantly, the two institutions 
previously mentioned supply about up to 83% of the Brazilian 
National Immunization Program demand, thereby reaching up 
to 179,855,000 national doses (116). A different situation can be 
found in Germany, where most of the vaccines are purchased 
from the private sector (90%) and 90% of them are financed by 
statutory insurance policies (117). The government provides the 
rest of the vaccines as part of special immunization programs. 
Recent studies have shown that no more than 0.47 and 0.25% 
of the German and Spanish healthcare budget, respectively, are 
addressed to vaccine production (117).
Due to the problems stated above, in the year 2000 an 
organization aimed to create alliances of vaccine manufactur-
ers in developing countries was established. This organization, 
known as the Developing Countries Vaccine Manufactures 
Network (DCVMN), includes near 50 vaccine manufacturers 
in 17 developing countries in Latin America, Africa, the Middle 
East, and Asia (118–120). The companies that are members of 
this organization produce more than 40 different vaccines, 
including the ones recommended by the WHO including BCG, 
polio, Hib, DTaP, and MMR (Table 2) (118, 120). Although the 
DCVMN main goal is to provide a high quality (cGMP compli-
ant) and sustainable supply of vaccines for developing countries, 
there are still not enough to provide the increasing demand of 
vaccines.
vaccine Shortages
The coverage of the national immunization programs relies on the 
available supply of vaccines. Several countries have experienced 
vaccine shortages at some point, which have included BCG, 
Hib, DTaP, pneumococcal conjugate, MMR, meningococcal, 
yellow fever, and influenza vaccines (121, 122). As an example, 
Sanofi Pasteur, one of the major producers of BCG, the current 
TABLe 2 | List of vaccine manufacturing centers companies of the countries reviewed in this work.
Name of company institute Country vaccines manufactured
Statens Serum Institute Denmark BCG
GlaxoSmithKline UK, Italy Meningococcal, tetanus toxoid, acelullar pertussis, reduced diphtheria 
toxoid, HPV, HepB, influenza, HepA, Hib, meningococcal, rabies, rotavirus
Seqirus UK Difteria and tetanus, cholera, HPV, HepB, JE, meningococcal, MMR, 
influenza, pneumococcal, rabies, rotavirus, HepA
Sanofi France Cholera, diphtheria, pertussis and tetanus, Hib, meningococcal, BCG, 
typhoid fever, dengue, HepA, HepB, influenza, JE, polio, rabies, yellow fever
Immunobiological Technology Guinhos (Bio-Manguinhos/Fiocruz) Brazil Yellow fever, polio, meningitis A, MMR, rotavirus, Hib, pneumococo
Butantan Institute Brazil Diphtheria toxoid and tetanus toxoid, DTP-whole cell, influenza, hemorrhagic 
fever/dengue, HepB, rabies
Sinergium Biotech Argentina Influenza, pneumococcal, HPV
ANLIS Argentina BCG, rabies, tetanus toxoid, yellow fever
Fundaçao Ataulpho de Paiva Brazil BCG
Birmex Mexico Diphtheria toxoid and tetanus toxoid, polio
Pfizer US Meningococcal, pneumococcal
Merck US BCG, HPV, Hib, MMR, pneumococcal, HepB, rotavirus, HepA, varicella
Serum Institute of India India DTP, MMR, Hib, meningococcal, influenza, BCG, HepB, Polio
Bharat Biotech International India Rotavirus, Hib, polio, DTP, influenza, rabies, typhoid
Kaketsukken Japan DTP, influenza, JE, HepB, rabies
China National Biotec Group Company Limited China DTP, BCG, influenza, Hib, hemorrhagic fever, JE, meningococcal, MMR, 
polio, rabies, rotavirus, varicella, yellow fever
BioNet Thailand Acelullar pertussis
Biofarma Indonesia BCG, diphtheria, tetanus, DTP-HepB-Hib, HepB, measles, polio
GreenSignal Bio Pharma Limited India BCG
IVAC Vietnam BCG, DTP
Pasteur Institute of Iran Iran BCG, HepB
Queen Saovabha Memorial Institute Thailand BCG, rabies
Vabiotec Vietnam Cholera
Vacsera Egypt Cholera, diphtheria, tetanus
Eubiologics South Korea Cholera, diphtheria, tetanus
Biological E. Limited India Diphtheria, tetanus, DTP, HepB, Hib, HepB, JE, tetanus toxoid
Instituto Finlay de Vacunas Cuba Tetanus toxoid, DTP
Indian Immunological Ltd. India Diphtheria toxoid and Tenatus toxoid, DTP, rabies
SK Chemicals Korea HepB, influenza, tetanus-diphtheria
Razi Irán DTP, MMR, polio
Haffkine India Polio
TiantianBio China Rubeolla
Torlak Institute Serbia BCG, diphtheria, tetanus
Biovac South Africa BCG
BCG, bacille Calmette–Guerin; HepB, hepatitis B virus; DTP, diphtheria, tetanus, and pertussis; MMR, mumps, measles, and rubella; Hib, Haemophilus influenzae type B; HPV, 
human papillomavirus; JE, Japanese encephalitis live vaccine.
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vaccine for TB, experienced significant manufacturing problems 
during 2012 and 2014. As a result, distribution of this vaccine 
was seriously compromised in several countries (123). Indeed, 
approximately 16.5 million doses shortfall of BCG occurred at 
the end of 2015 was estimated, using mathematical models, to 
be associated with 7,433 excess of TB deaths worldwide (124). 
In 2015, short supplies for the meningococcal vaccine worldwide 
threatened the health of the population in Nigeria, a place where 
an important epidemic of meningitis took place (125). An addi-
tional example is the Hib boost vaccine, for which doses were not 
available in the USA from December 2007 to September 2009 
(122). Moreover, several physicians have reported shortages of 
influenza vaccines, especially for high-risk populations in the 
USA during the years 2004–2005 (126). Further, Africa and the 
USA have also experienced shortages for the yellow fever vaccine 
during the last 2 years (127–129). Similarly, significant shortages 
of the pneumococcal conjugate vaccine occurred during the 
period 2003–2004, causing an important decrease of 10.6% of the 
coverage of >4 doses of the seven-valent pneumococcal conjugate 
vaccine in 16-month-old children (130). Likewise, such shortage 
issues have prompted the concern of elaborating protocols for 
ensuring availability of those vaccines for at least the high-risk 
populations (131). Because the pandemic of influenza is highly 
extensive, the demand for this vaccine worldwide is very high, 
causing sometimes problems of vaccine shortage (132, 133). This 
situation is particularly dramatic when pandemics on influenza 
arise, such as the H1N1 in 2009 (134).
Different reasons can explain disruptions of the vaccine sup-
plies, such as vaccines that leave the market, problems in the pro-
duction, loss of the GMP in manufacturing centers/companies, 
and changes in the formulation of vaccines (135). An important 
correlation is that fewer vaccine manufacture suppliers exist for 
one vaccine the larger the impact of supply shortage can have 
on the population (135). To solve the vaccine shortage in case 
of epidemics, global vaccine stockpiles have been established for 
vaccines, including smallpox, meningococcal, yellow fever, oral 
cholera, and pandemic influenza vaccines (136). Moreover, the 
challenge for institutions, such as the Brazilian government, is 
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to make investments for local vaccine development and manu-
facturing to avoid international dependency and the threat of 
shortage (116).
gLOBAL eMeRgiNg DiSeASeS AND 
ANTiBiOTiC ReSiSTANCe
The Ebola, Zika, and influenza virus pandemics are examples 
of worldwide emergencies that have recently affected various 
regions of the planet. In 2009, the H1N1 influenza pandemic 
resulted in the highest number of cases in Mexico (134). In April 
of 2009, the first cases with severe respiratory disease started to be 
concentrated in the Federal District of Mexico’s most populated 
area. The Mexico’s National Institute of Respiratory Disease 
struggled with such situation to contain the propagation of the 
influenza virus (137). Months later, the H1N1 virus was spread to 
over 213 countries causing 16,226 deaths and the WHO declared 
it to be the first flu outbreak in the last 41 years (138). The H1N1 
2009 pandemic was identified as a new influenza A subtype of 
swine origin, and consequently, at that moment no vaccines were 
available. After that outbreak, a vaccine was rapidly developed, 
include the 2009 H1N1 influenza virus antigen in order to protect 
against that virus (139). However, if new mutations arise resulting 
in a new pandemic subtype, then the available vaccine will be 
useless and again no vaccine will be accessible to protect against 
a potential new virulent strain with a high rate of mortality, such 
as seen with the previous H1N1 influenza A virus pandemics.
In 2014, West Africa experienced a devastating outbreak of 
Ebola and multiple countries were affected. In response to that situ-
ation, several countries and institutions such as the WHO and the 
CDC activated emergency operations to control the situation (98). 
Although the end of transmission of Ebola was reported in Liberia 
and in Guinea, still the WHO in Guinea, Liberia and Sierra Leone 
has still reported a total of 28,616 Ebola cases, with 11,310 deaths 
(140). Ebola virus is associated with hemorrhagic fever and is 
transmitted by corporal fluids. No vaccine or treatment is avail-
able for this virus; thereby efforts in that situation were to limit 
transmission of the disease.
On the other hand, according to the CDC, most of the Zika 
virus cases have been reported in many countries of South 
America, Africa, Asia, and the USA (141). This virus is transmit-
ted by a mosquito-borne (Aedes aegypti) and symptoms include 
mild fever, headache, arthralgia, myalgia, non-purulent conjunc-
tivitis, and a pruritic maculopapular rash (142). However, the 
most concerning effect that has been associated with Zika virus 
is the prenatal microcephaly (143).
According to the WHO-vaccine pipeline tracker, vaccines 
against AIDS, malaria, enteric pathogens, including human 
norovirus, the respiratory syncytial virus, Zika virus, Dengue 
virus, and pulmonary TB are in different stages of development. 
Some of these diseases, such as AIDS or pulmonary TB have 
been a concerning problem, since for several years have not been 
obtained a definitive cure or an efficient vaccine to prevent them. 
In addition, other diseases, such as the ones caused by the Zika 
virus, have had emergency problems that have required a rapid 
response. One prompt response strategy for the past Ebola out-
breaks has been the use of anti-Ebola antibodies from the blood 
of disease survivors. Therefore, strategies with monoclonal anti-
bodies to treat Ebola are currently being studied (144). Moreover, 
research on nanoparticles, adenovirus-based, modified Vaccinia 
Ankara-based, and recombinant-rabies vaccines against Ebola 
are ongoing, even in phase I, II and III of clinical trials (98, 145). 
From Ebola vaccines in clinical trials so far, the most advanced 
one is a recombinant vesicular stomatitis virus–Zaire Ebola virus 
(rVSV-ZEBOV) vaccine that has been licensed to Merck and 
recently, showed to be effective in susceptible individuals (146). 
On the other hand, strategies such as adenovirus-based recombi-
nant vaccines and cell culture-derived inactivated vaccines using 
BHK and Vero cells are under research for Zika virus vaccine 
development (147). Despite the research ongoing about Zika and 
Ebola viruses, or other common and fastidious viruses such as 
respiratory syncytial virus and human norovirus, no vaccines or 
efficient treatment are still available. Thus, high technology cent-
ers are urgently needed to provide a solution to these problems 
and offer a rapid response to global health emergency states.
As emerging diseases, microorganisms with multiple 
resistances to antimicrobial agents have been reported in the 
past years. Bacteria resistance to the available antimicrobial 
agents, such as Klebsiella pneumoniae, Staphylococcus aureus, 
Escherichia coli, and Mycobacterium tuberculosis have alarmed 
health care worldwide for their resistance to antimicrobial 
agents (148–151). Furthermore, availability of an effective 
therapy for patients infected with those microorganisms is 
limited and more research and development is needed (152). 
Despite policies concerning the use of antimicrobials and the 
development of new drugs, it is urgent to increase the vaccine 
manufacturing capacity to prevent the spreading of these infec-
tions with multiple antibiotic resistance (153).
CONCLUDiNg ReMARKS
There is no doubt that many diseases have been prevented 
due to the implementation of extensive vaccination programs. 
Domestic health public systems worldwide are committed 
to increase vaccination coverage for the population through 
national immunization programs. Thus, the WHO recommends 
to immunize children with BCG, DTaP, MMR, and vaccines 
to prevent hepatitis B, poliovirus, Hib, several serotypes of 
S. pneumoniae, rotavirus, and HPV. However, not all these vac-
cines are included in the national immunization programs of most 
countries. Not only the problem is the inclusion of some vaccines 
in local programs of immunizations but also the cost associated 
with its production, implementation, and delivery are part of the 
barriers. In this line, it is important to highlight the effort of some 
organizations such the WHO, the PATH, the GAVI Alliance, the 
UNICEF, the Bill & Melinda Gates Foundation, among others, 
to include as much population as possible in these immuniza-
tion global strategies. Furthermore, shortages around the world 
have taken places during the past years, which have underscored 
the necessity to improving the capacities and infrastructure to 
produce and distribute vaccines. It is important to underscore 
the role played by new countries manufacturing vaccines, which 
include Brazil, the Russian Federation, India, China and South 
Africa (a group known as BRICS). Such local production has 
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contributed to ensuring access to traditional vaccines and to 
maintaining the stability of immunization programs in develop-
ing countries. Also, an important gap between industrialized and 
developing countries prevails in this field. Further, Ebola, Zika, 
influenza virus pandemics, and antimicrobial resistance have 
raised alarms, questioning whether we are prepared to control 
rapidly and efficiently viral pandemics worldwide.
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